Veerle Van Dooren

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +14

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

Marion Procter, Thomas Suter, Evandro de Azambuja et al. · Journal of Clinical Oncology · 2010 · 245 citations

Medicine, Cardiology, Oncology +17

¹⁸F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Géraldine Gebhart, Eileen Holmes, Javier Robles et al. · Journal of Nuclear Medicine · 2013 · 159 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer

José Baselga, Ian Bradbury, Holger Eidtmann et al. · Cancer Research · 2010 · 116 citations

Medicine, Oncology, Pharmacology +15

Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience

Otto Metzger, Evandro de Azambuja, Ian Bradbury et al. · The Oncologist · 2013 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +17